A comparative study of Integrin-linked kinase 1 and anti-smith antibody as diagnostic biomarkers in Iraqi patients with systemic lupus erythematosus
Keywords:
systemic lupus erythematosus, integrin-linked kinase 1, anti-smith antibody, lupus nephritisAbstract
Systemic lupus erythematosus (SLE) is the prototypical multisystem autoimmune disease, with a broad spectrum of clinical manifestations affecting virtually all organs and tissues. Determination of integrin-linked kinase 1 (ILK- 1) and anti-smith antibody (ASAB) levels in serum of Iraqi patients with systemic lupus erythematosus; that ILK-1 may serve as a diagnostic marker for SLE disease; and evaluation of the impact of systemic lupus erythematosus on renal function in these patients. This study included 100 female patients with systemic lupus erythematosus from the Rheumatology Unit at the Baghdad Teaching Hospital, Medical City, (Baghdad), as well as 30 healthy females without any chronic diseases who served as the control group. All study participants’ ages ranged between 18 and 48 years. Using Rheuma Helper, all patients were classified based on the SLE disease activity index (SLEDAI) severity into 30 female patients with mild stage (Gl), 40 female patients with moderate stage (G2), and 30 female patients with severe stage (G3). (G3). Results: As compared to the control (C) group, the Gl, G2, and G3 patient groups in the current investigation showed a substantial increase in the levels of dsDNA, ANA, ASAB, ILK-1, urea, and uric acid. Comparing the control group to Gl, G2, and G3, the levels of creatinine did not differ. The current results showed that there were various significant comparisons between ILK-1 and other study parameters in the control and patient groups. ROC test for ILK-1 and ASAB markers showed a perfect cut-off value with 100% sensitivity and 100% specificity. Conclusions: TK-1 may be helpful as a novel biomarker in the diagnosis of SLE disease, and there was a positive correlation between ILK-1 with urea and creatinine which are considered factors of renal damage. As a result, these patients may be at risk for renal failure at a severe stage. This indicates that SLE disease has an impact on kidney function.
Downloads
References
I.Zaidan, T.F., Oral manifestations, oral health status and
saliva composition changes in a sample of Iraqi
systemic lupus erythematosus patients. Scientific
Journal Published by the College of DentistryUniversity of Baghdad, 2012: p. 65.
Tawfeq, A., A.F. Al-Rubaye, and M.M.H. AL-Murshidi,
Cross Sectional Study of the Correlation between ESR,
RBCS and WBCs with Disease Duration in Iraqi
Patients with Systemic Lupus Erythematosus Disease
(SLE). Indian Journal of Forensic Medicine & Toxicology,
14(3): p. 2579-2583.
Abdulridha, R.H., A.M. Saud, and M.H. Alosami, Evaluation
of Interferon Alpha (IFN- ) in Women with Systemic
Lupus Erythematosus in Iraq. Iraqi Journal of Science,
: p. 4225-4233.
Rees, F., et al., The worldwide incidence and prevalence of
systemic lupus erythematosus: a systematic review of
epidemiological studies. Rheumatology, 2017. 56(11): p.
-1961.
Dahham, Z.M. and N.I. Haddad, Circulating Levels of
Interferon Regulatory Factor-5 Correlates with Disease
Activity in Systemic Lupus Erythematosus Iraqi
Patients. J Contemp Med Sci| Vol, 2022. 8(6): p. 388-
Migliorini, P., et al., Anti-Sm and anti-RNP antibodies.
Autoimmunity, 2005. 38(1): p. 47-54.
Zieve, G.W. and P.R. Khusial, The anti-Sm immune
response in autoimmunity and cell biology.
Autoimmunity reviews, 2003. 2(5): p. 235-240.
G6rska, A. and A.J. Mazur, Integrin-linked kinase (ILK):
the known vs. the unknown and perspectives. Cellular
and Molecular Life Sciences, 2022. 79(2): p.100.
Wickstrdm, S.A., et al., The ILK/PINCH/parvin complex:
the kinase is dead, long live the pseudokinase! The
EMBO journal, 2010. 29(2): p. 281-291.
lO.Kretzler, M., et al., Integrin linked kinase as a candidate
downstream effector in proteinuria. The FASEB
Journal, 2001.15(10): p. 1843-1845.
Ali, A. and S. Al-Windawi, Tubulointerstitial lupus
nephritis. Journal of nephropathology, 2013. 2(1): p. 75.
Parikh, S.V., et al., Update on lupus nephritis: core
curriculum 2020. American Journal of Kidney Diseases,
76(2): p. 265-281.
Anders, H.-J., et al., Lupus nephritis (Primer). Nature
Reviews: Disease Primers, 2020. 6(1).
Petri, M., E. Barr, and L.S. Magder, Risk of renal failure
within 10 or 20 years of systemic lupus erythematosus
diagnosis. The Journal of rheumatology, 2021. 48(2): p.
-227.
Bertsias, G., R. Cervera, and D.T. Boumpas, Systemic
lupus erythematosus: pathogenesis and clinical
features. EULAR textbook on rheumatic diseases, 2012.
: p. 476-505.
Gorial, F.I., Z.A. Mahmood, and S. Al Obaidi, Body
composition in Iraqi Women with systemic lupus
erythematosus. Glob J Health Sci, 2019. 11(1): p. 63-70.
Andrade, R.M., et al., Accelerated damage accrual
among men with systemic lupus erythematosus: XLIV.
Results from a multiethnic US cohort. Arthritis &
Rheumatism: Official Journal of the American College
of Rheumatology, 2007. 56(2): p. 622-630.
Barcia Sixto, L. and D. Isenberg, Systemic lupus
erythematosus: causes and manifestations. Trends in
Urology & Men's Health, 2020.11(1): p. 26-29.
Pashnina, I.A., et al., Antinuclear autoantibodies in
health: autoimmunity is not a synonym of autoimmune
disease. Antibodies, 2021.10(1): p. 9.
O.Abdualkader, S.N., et al., Correlation between
lnterleukin-4 and lnterleukin-6 and auto antibodies in
Systemic Lupus Erythematosus. Journal of the Faculty
of Medicine Baghdad, 2009. 51(4): p. 416-418.
Arbuckle, M.R., et al., Development of autoantibodies
before the clinical onset of systemic lupus
erythematosus. New England Journal of Medicine,
349(16): p. 1526-1533.
van Beers, J.J. and M.W. Schreurs, Anti-Sm antibodies in
the classification criteria of systemic lupus
erythematosus. Journal of Translational Autoimmunity,
: p. 100155.
Elustondo, P., et al., Integrin-linked kinase (ILK) is highly
expressed in first trimester human chorionic villi and
regulates migration of a human cytotrophoblastderived cell line. Biology of reproduction, 2006. 74(5): p.959-968.
Ton, C., A. Mui, and S. Dedhar, Integrin-linked kinase
regulates inducible nitric oxide synthase and
cyclooxygenase-2 expression in an NF- B-dependent
manner. Journal of Biological Chemistry, 2002. 277(5):
p. 3109-3116.
Ahmed, A.U., et al., Integrin-linked kinase expression in
myeloid cells promotes inflammatory signaling during
experimental colitis. The Journal of Immunology, 2017.
(6): p. 2128-2139.
de Frutos, S., et al., Chronic kidney disease induced by an
adenine rich diet upregulates integrin linked kinase (ILK)
and its depletion prevents the disease progression.
Biochimica et Biophysica Acta (BBA)-Molecular Basis of
Disease, 2019. 1865(6): p. 1284-1297.
Ibrahim, N., et al., Estimation of some immunological
markers of Iraqi patients in systemic lupus
erythematosus with lupus nephritis. Prof.(Dr) RK
Sharma, 2020. 20(4): p. 4668.
Cervera, R., Systemic lupus erythematosus in Europe at
the change of the millennium: lessons from the "Euro¬
Lupus Project". Autoimmunity reviews, 2006. 5(3): p.
-186.
AL-Qubaeissy, K.Y., et al., Does Rheumatoid Factor have
any Protective Role in Patients with Lupus Nephritis.
Editorial Board, 2020.
Block, S., A brief history of twins. 2006, Sage
Publications Sage CA: Thousand Oaks, CA. p. 61-64.
Yang, Z., et al., Associations of serum urea, creatinine and uric acid with clinical and laboratory features in patients with systemic lupus erythematosus. Rheumatology international, 2012. 32: p. 2715-2723.
Sham, S., A Study on QT Interval in patients with SLE and its Correlation with disease activity and Auto Antibodies. 2014, Madras Medical College, Chennai.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
